Posted by Michael Wonder on 05 Sep 2022
Forxiga approved in China for the treatment of chronic kidney disease in patients at risk of progression with and without type 2 diabetes
5 September 2022 - Approval marks the first SGLT-2 inhibitor approved in China for chronic kidney disease in adult patients with and without type 2 diabetes mellitus.
AstraZeneca’s Forxiga (dapagliflozin) has been approved in China to reduce the risk of sustained estimated glomerular filtration rate decline, end-stage kidney disease, cardiovascular death and hospitalisation for heart failure in adults with chronic kidney disease at risk of progression with and without type 2 diabetes mellitus.
